Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × lanreotide × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 10 NET 7 Gastrointestinal 2 Tumor-Agnostic 1 Genitourinary 1

Conditions

Neoplasm Metastasis 1

Interventions

Paclitaxel 26 Carboplatin 25 Gemcitabine 22 pembrolizumab 21 Nivolumab 20 Cisplatin 15 Bevacizumab 14 Docetaxel 13 Pemetrexed 12 Ipilimumab 12 Erlotinib Hydrochloride 12 Capecitabine 12 Fluorouracil 11 Irinotecan 10 Afatinib 10 eribulin 9 BI 6727 9 130-nm albumin-bound paclitaxel 9 Radiotherapy 8 Magnetic Resonance Spectroscopy 8 Leucovorin 8 Everolimus 8 Cyclophosphamide 8 Albumin-Bound Paclitaxel 8 olaparib 7 Oxaliplatin 7 lenvatinib 6 avelumab 6 Trastuzumab 6 Cetuximab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02288377 2023-01-18

REMINET

Federation Francophone de Cancerologie Digestive

Phase 2/3 Terminated

53 enrolled 11 charts

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡